The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1.
Antibody protection against flaviviruses is associated with the development of neutralizing antibodies against the viral envelope (E) protein. Prior studies with West Nile virus (WNV) identified therapeutic mouse and human monoclonal antibodies (MAbs) that recognized epitopes on domain III (DIII) of...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2010-04-01
|
| Series: | PLoS Pathogens |
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20369024/pdf/?tool=EBI |
| _version_ | 1818930650900594688 |
|---|---|
| author | Bimmi Shrestha James D Brien Soila Sukupolvi-Petty S Kyle Austin Melissa A Edeling Taekyung Kim Katie M O'Brien Christopher A Nelson Syd Johnson Daved H Fremont Michael S Diamond |
| author_facet | Bimmi Shrestha James D Brien Soila Sukupolvi-Petty S Kyle Austin Melissa A Edeling Taekyung Kim Katie M O'Brien Christopher A Nelson Syd Johnson Daved H Fremont Michael S Diamond |
| author_sort | Bimmi Shrestha |
| collection | DOAJ |
| description | Antibody protection against flaviviruses is associated with the development of neutralizing antibodies against the viral envelope (E) protein. Prior studies with West Nile virus (WNV) identified therapeutic mouse and human monoclonal antibodies (MAbs) that recognized epitopes on domain III (DIII) of the E protein. To identify an analogous panel of neutralizing antibodies against DENV type-1 (DENV-1), we immunized mice with a genotype 2 strain of DENV-1 virus and generated 79 new MAbs, 16 of which strongly inhibited infection by the homologous virus and localized to DIII. Surprisingly, only two MAbs, DENV1-E105 and DENV1-E106, retained strong binding and neutralizing activity against all five DENV-1 genotypes. In an immunocompromised mouse model of infection, DENV1-E105 and DENV1-E106 exhibited therapeutic activity even when administered as a single dose four days after inoculation with a heterologous genotype 4 strain of DENV-1. Using epitope mapping and X-ray crystallographic analyses, we localized the neutralizing determinants for the strongly inhibitory MAbs to distinct regions on DIII. Interestingly, sequence variation in DIII alone failed to explain disparities in neutralizing potential of MAbs among different genotypes. Overall, our experiments define a complex structural epitope on DIII of DENV-1 that can be recognized by protective antibodies with therapeutic potential. |
| first_indexed | 2024-12-20T04:04:05Z |
| format | Article |
| id | doaj.art-df704f99bc524bef9b9a3a5bc6a7a1a1 |
| institution | Directory Open Access Journal |
| issn | 1553-7366 1553-7374 |
| language | English |
| last_indexed | 2024-12-20T04:04:05Z |
| publishDate | 2010-04-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS Pathogens |
| spelling | doaj.art-df704f99bc524bef9b9a3a5bc6a7a1a12022-12-21T19:54:05ZengPublic Library of Science (PLoS)PLoS Pathogens1553-73661553-73742010-04-0164e100082310.1371/journal.ppat.1000823The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1.Bimmi ShresthaJames D BrienSoila Sukupolvi-PettyS Kyle AustinMelissa A EdelingTaekyung KimKatie M O'BrienChristopher A NelsonSyd JohnsonDaved H FremontMichael S DiamondAntibody protection against flaviviruses is associated with the development of neutralizing antibodies against the viral envelope (E) protein. Prior studies with West Nile virus (WNV) identified therapeutic mouse and human monoclonal antibodies (MAbs) that recognized epitopes on domain III (DIII) of the E protein. To identify an analogous panel of neutralizing antibodies against DENV type-1 (DENV-1), we immunized mice with a genotype 2 strain of DENV-1 virus and generated 79 new MAbs, 16 of which strongly inhibited infection by the homologous virus and localized to DIII. Surprisingly, only two MAbs, DENV1-E105 and DENV1-E106, retained strong binding and neutralizing activity against all five DENV-1 genotypes. In an immunocompromised mouse model of infection, DENV1-E105 and DENV1-E106 exhibited therapeutic activity even when administered as a single dose four days after inoculation with a heterologous genotype 4 strain of DENV-1. Using epitope mapping and X-ray crystallographic analyses, we localized the neutralizing determinants for the strongly inhibitory MAbs to distinct regions on DIII. Interestingly, sequence variation in DIII alone failed to explain disparities in neutralizing potential of MAbs among different genotypes. Overall, our experiments define a complex structural epitope on DIII of DENV-1 that can be recognized by protective antibodies with therapeutic potential.https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20369024/pdf/?tool=EBI |
| spellingShingle | Bimmi Shrestha James D Brien Soila Sukupolvi-Petty S Kyle Austin Melissa A Edeling Taekyung Kim Katie M O'Brien Christopher A Nelson Syd Johnson Daved H Fremont Michael S Diamond The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathogens |
| title | The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. |
| title_full | The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. |
| title_fullStr | The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. |
| title_full_unstemmed | The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. |
| title_short | The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. |
| title_sort | development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1 |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20369024/pdf/?tool=EBI |
| work_keys_str_mv | AT bimmishrestha thedevelopmentoftherapeuticantibodiesthatneutralizehomologousandheterologousgenotypesofdenguevirustype1 AT jamesdbrien thedevelopmentoftherapeuticantibodiesthatneutralizehomologousandheterologousgenotypesofdenguevirustype1 AT soilasukupolvipetty thedevelopmentoftherapeuticantibodiesthatneutralizehomologousandheterologousgenotypesofdenguevirustype1 AT skyleaustin thedevelopmentoftherapeuticantibodiesthatneutralizehomologousandheterologousgenotypesofdenguevirustype1 AT melissaaedeling thedevelopmentoftherapeuticantibodiesthatneutralizehomologousandheterologousgenotypesofdenguevirustype1 AT taekyungkim thedevelopmentoftherapeuticantibodiesthatneutralizehomologousandheterologousgenotypesofdenguevirustype1 AT katiemobrien thedevelopmentoftherapeuticantibodiesthatneutralizehomologousandheterologousgenotypesofdenguevirustype1 AT christopheranelson thedevelopmentoftherapeuticantibodiesthatneutralizehomologousandheterologousgenotypesofdenguevirustype1 AT sydjohnson thedevelopmentoftherapeuticantibodiesthatneutralizehomologousandheterologousgenotypesofdenguevirustype1 AT davedhfremont thedevelopmentoftherapeuticantibodiesthatneutralizehomologousandheterologousgenotypesofdenguevirustype1 AT michaelsdiamond thedevelopmentoftherapeuticantibodiesthatneutralizehomologousandheterologousgenotypesofdenguevirustype1 AT bimmishrestha developmentoftherapeuticantibodiesthatneutralizehomologousandheterologousgenotypesofdenguevirustype1 AT jamesdbrien developmentoftherapeuticantibodiesthatneutralizehomologousandheterologousgenotypesofdenguevirustype1 AT soilasukupolvipetty developmentoftherapeuticantibodiesthatneutralizehomologousandheterologousgenotypesofdenguevirustype1 AT skyleaustin developmentoftherapeuticantibodiesthatneutralizehomologousandheterologousgenotypesofdenguevirustype1 AT melissaaedeling developmentoftherapeuticantibodiesthatneutralizehomologousandheterologousgenotypesofdenguevirustype1 AT taekyungkim developmentoftherapeuticantibodiesthatneutralizehomologousandheterologousgenotypesofdenguevirustype1 AT katiemobrien developmentoftherapeuticantibodiesthatneutralizehomologousandheterologousgenotypesofdenguevirustype1 AT christopheranelson developmentoftherapeuticantibodiesthatneutralizehomologousandheterologousgenotypesofdenguevirustype1 AT sydjohnson developmentoftherapeuticantibodiesthatneutralizehomologousandheterologousgenotypesofdenguevirustype1 AT davedhfremont developmentoftherapeuticantibodiesthatneutralizehomologousandheterologousgenotypesofdenguevirustype1 AT michaelsdiamond developmentoftherapeuticantibodiesthatneutralizehomologousandheterologousgenotypesofdenguevirustype1 |